BridgeMD
Ephedrine 0.15 mg/kg for reducing onset time of rocuronium 0.6 mg/kg in elderly patients.
EU CTIS ID: 2024-517933-42-00
What this study is testing
The aim of this study is to determine the onset time of rocuronium after administration of ephedrine 0.15 mg/kg in patients with age ≥ 80 years.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients ≥ 80 years old
- Informed consent
- Scheduled for elective surgery (expected duration of anesthesia >1 hour) under general anesthesia with intubation and use of rocuronium
- American Society of Anesthesiologists (ASA) physical status classification I to III
- Can read and understand Danish
You likely can't join if
- Known allergy to rocuronium or ephedrine
- Neuromuscular disease that may interfere with neuromuscular data
- Indication for rapid sequence induction
- Daily use of beta-blocking agents
- Known cardiac arrythmia (atrial fibrillation, supraventricular or ventricular)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.